SELLAS Life Sciences Group, Inc.

US$8.42As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:SLSHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR (34.07%)
Div yield —
ROE (39.63%)
Biotechnology
Beta (5Y) 2.71
PE TTM —
TSR TTM 362.64%
Mkt cap US$1.700B
ROIC (25.05%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$10
19.87%
(52.60%)
Buy 11|10|5|3|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.08
0.09
0.10
0.09
11.15%
12.24%
21.49%
10.32%
Revenue$M
230.6
240.0
238.9
243.3
5.18%
4.35%
6.79%
8.24%
Peers (US$1.700B)
Cap (US$)
PE
1.672B
5.690x
1.713B
—
Capital
TTM
5Y
10Y
Leveragex
0.616
0.023
0.018
EBIT/Intx
0.608
0.793
0.764
Own earn%
(84.16)
(485.82)
(433.37)
Sh yield%
33.61
6.98
9.63
Owners
Insiders/Inst%
9.94
50.47
Short interest%
3.07
SBC / revenue%
1.13
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
6–12
$1 testx
—
Incr. ROIC%
51